Company Overview
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +105.64% |
| 6 Months: | +29.98% |
| 3 Months: | -6.64% |
| 1 Month: | +4.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.07 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 31.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LONA LeonaBio, Inc. PHARMA | 8.02 | -0.35 | $75.56M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -1.53M | -1.27M | -2.25M | -7.40M | -10.78M | -16.64M | -17.83M | -23.39M | -23.57M | -24.13M | -29.77M | -31.64M | -35.04M | -27.69M | -28.03M | -29.62M | -9.54M | -7.29M | -6.87M | -17.21M |
| Net Income | -1.53M | -1.80M | -1.99M | -8.46M | -8.87M | -13.97M | -15.67M | -20.98M | -24.34M | -20.19M | -27.82M | -29.60M | -32.97M | -26.34M | -26.86M | -28.74M | -9.14M | -6.97M | -6.61M | -32.95M |
| Diluted EPS | - | - | - | - | - | - | -0.42 | -0.56 | -0.65 | -0.53 | -0.73 | -0.78 | -0.87 | -0.69 | -0.70 | -7.46 | -2.34 | -0.18 | -1.68 | -1.73 |
| R&D Expense | 1.03M | 592.00K | 1.68M | 5.83M | 7.45M | 12.02M | 10.71M | 14.46M | 14.80M | 16.96M | 21.29M | 21.61M | 27.20M | 21.24M | 22.15M | 17.92M | 4.30M | 3.66M | 2.83M | 11.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -5.45M | -20.00M | -64.02M | -104.02M | -125.47M | -100.90M | -102.27M |
| Net Income | -5.16M | -19.95M | -54.85M | -95.64M | -117.67M | -96.94M | -105.61M |
| Diluted EPS | - | - | -1.49 | -2.53 | -3.09 | -25.19 | -24.70 |
| R&D Expense | 3.79M | 13.29M | 42.79M | 61.46M | 93.79M | 70.68M | 17.50M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.19M | 279.56M | 332.01M | 258.15M | 160.25M | 58.78M | 92.15M |
| Total Equity | -14.89M | -19.72M | 274.28M | 321.08M | 235.14M | 130.19M | 44.84M | 27.79M |
| Cash & Equivalents | - | 2.06M | 60.62M | 110.54M | 95.97M | 90.58M | 48.44M | 69.28M |
| Total Liabilities | - | 4.86M | 5.28M | 10.92M | 23.02M | 30.06M | 13.94M | 64.36M |
| Current Liabilities | - | 1.27M | 4.41M | 9.29M | 21.43M | 28.84M | 13.13M | 47.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.71M | -24.11M | -43.10M | -72.47M | -100.75M | -97.17M | -45.73M |
| Investing Cash Flow | 1.51M | -210.07M | -4.08M | 57.66M | 95.09M | 54.83M | -15.89M |
| Financing Cash Flow | 946.00K | 292.75M | 97.09M | 654.00K | 493.00K | 194.00K | 82.46M |
| Capital Expenditure | - | -2.32M | -1.57M | -1.14M | -304.00K | -33.00K | - |
| Free Cash Flow | - | -26.43M | -44.67M | -73.61M | -101.06M | -97.20M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 26.2% | -7.3% | -17.1% | -40.7% | -90.4% | -216.2% | -380.0% |
| ROCE % | -594.9% | -7.3% | -19.8% | -43.9% | -95.5% | -221.1% | -229.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Perceptive Advisors Llc | 19.79% | 1.86M | $12.62M |
| 2 | Adar1 Capital Management, LLC | 8.27% | 777.10K | $5.28M |
| 3 | Acorn Capital Advisors, LLC | 6.76% | 634.54K | $4.31M |
| 4 | Commodore Capital Lp | 4.94% | 464.40K | $3.15M |
| 5 | NEA Management Company, LLC | 4.94% | 464.40K | $3.15M |
| 6 | TCG Crossover Management, LLC | 4.94% | 464.40K | $3.15M |
| 7 | Spruce Street Capital LP | 4.19% | 393.70K | $2.67M |
| 8 | Kalehua Capital Management LLC | 4.19% | 393.70K | $2.67M |
| 9 | Blackstone Inc | 3.46% | 324.64K | $2.20M |
| 10 | Adage Capital Partners GP L.L.C. | 3.19% | 300.00K | $2.04M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LONA
A drug developer's New York fireside chat is set for Sept. 11 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPWjRNeEFzQ3pQYlllMzB0andEQ25GdS1GWmI5bTJaeDV5Z1ZYazZRcUNRRnlnay1OLWVKcTY5OXZWLWR2WHdZNUNGUVc5R3IzTi11LURyREN5dHVveloyRkN0UmM3UWFJU2s1TUdOOS12dFZILWpkclpYRkN6RzVNWlRWWjRveE9VUnoyT1…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBLRk9EdGZzQ1RwODBsWnRvTXE3Y053UmRCNHJiTm9ub2xlbVBudWpSdWhncDdXakgxZ1JQN1I3MjF4NVhlazRuSTd5RnlpMzQt?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Citizens lowers LeonaBio stock price target to $17 on valuation - Investing.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNOU4xM0tmejVpbHVEVUcxRENQOVVfaEdKMzBSOENjV0JTZlgzZU8tUUNzcVZLRlNJX3pEeEZLV19GbXFzLWhULWMyWHZzVWhfQmNEWE9VNHhVUTUxaUdZOWRsUUVuZHpaTTYwVDUwdVN2VU1wdFBVbDZzTjhSSk85dGhmdjdsUGZLNVR3dU…
Analysts Are Bullish on These Healthcare Stocks: Cooper Co (COO), LeonaBio (LONA) - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxPUlhJZEU4QmF6VzEzV2EtV2VBVkhjVi1Haldybkg2dkIzN0dLc1E3LUxhN25oZFBrOVlxS3kzSnhXaUdyOVVhVzFYWVFFN0FqNzZYRnlqcXl6T1ZROThjOUF3Zi1qUGc1dkhLNDVpUlBoQl9ta0s5RGUtZU9jVjhzUkE1RV94R2lsLTQzUT…
LONA Stock Price and Chart — NASDAQ:LONA - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE44bEtlS0VvX1YtYmpJVkI4T3o3VVR6eVkyVmQzaTc1NXdGenhlUGMzcTNSQ2ZrNXJsaHhwQnBWXzFvVl80blhCSkpNNFR4UVJYRVNxN2JkVWNZZTJO?oc=5" target="_blank">LONA Stock Price and Chart — NASDAQ:LONA</a…
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxNSXlqYmRiRWFnNGxkbXVOc2hNUmtKTTI5cmhBQm1EbnRWRTNLbV9rUktWZXFHWU1PQ2Z6Qmd6a0c0Y2lXaWVEek83SGRfSzZnS1FqTUk3MnRGQ1ZzQWZKSkxXQzQtc245YXZXVmROanN5WFFoS1J5MWdEMksyZFlKcmNSRnphMTRH?oc=5"…
LONA — Frequently Asked Questions
What is the current share price of LeonaBio, Inc. (LONA)?
As of 2026-09-19 21:16 PDT, LeonaBio, Inc. (LONA) trades at $8.02 on NasdaqCM. Its 52-week range is $3.60 to $11.68.
What is the market capitalisation of LONA?
LeonaBio, Inc. (LONA) has a market capitalisation of $75.56M on NasdaqCM.
What is the P/E ratio of LONA?
LONA trades at a trailing price-to-earnings (P/E) ratio of -0.35. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.90.
Is LONA a good stock to buy?
This page provides a data-driven analysis of LeonaBio, Inc. (LONA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.